The impact of pre-existing antibody on subsequent immune responses to meningococcal A-containing vaccines

Vaccine

Volumn 32, Issue 33, 2014, Pages 4220-4227

  Idoko, Olubukola T ^a   Okolo, Seline N ^b   Plikaytis, Brian ^c   Akinsola, Adebayo ^a   Viviani, Simonetta ^d   Borrow, Ray ^e   Carlone, George ^c   Findlow, Helen ^e   Elie, Cheryl ^c   Kulkarni, Prasad S ^f   Preziosi, Marie Pierre ^g   Ota, Martin ^a,h   Kampmann, Beate ^a,i  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF JOS   (Nigeria)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d Meningitis Vaccine Project   (France)

^e MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^f Serum Institute of India Ltd   (India)

^g WORLD HEALTH ORGANIZATION   (Switzerland)

^h WHO REGIONAL OFFICE FOR AFRICA   (Congo)

ⁱ IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antibody; Conjugate vaccine; Immune response; Meningococcal A; Pre existing

Indexed keywords

IMMUNOGLOBULIN G; MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; BACTERIUM ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GAMBIA; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERUM BACTERICIDAL ANTIBODY ASSAY; VACCINATION; YOUNG ADULT; AGE; BLOOD; CLINICAL TRIAL; HUMORAL IMMUNITY; MENINGITIS, MENINGOCOCCAL; PRESCHOOL CHILD;

ADOLESCENT; ADULT; AGE FACTORS; ANTIBODIES, BACTERIAL; CHILD; CHILD, PRESCHOOL; FEMALE; GAMBIA; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULIN G; MALE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; SERUM BACTERICIDAL ANTIBODY ASSAY; YOUNG ADULT;

EID: 84903461899     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.04.052     Document Type: Article

References (47)

1. Greenwood B. Editorial: 100 years of epidemic meningitis in West Africa - has anything changed?. Trop Med Int Health 2006, 11:773-780.
2. Novak R.T., Kambou J.L., Diomande F.V., Tarbangdo T.F., Ouedraogo-Traore R., Sangare L., et al. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis 2012, 12:757-764.
3. Lapeyssonnie L., Louis J., Bonnardot R., Lefevre M. [Ist note concerning the activity of a single dose of sulfamethoxypyridazine by intramuscular route in the treatment of meningococcal cerebrospinal meningitis]. Med Trop (Mars) 1961, 21:129-133.
4. Greenwood B. Manson lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 1999, 93:341-353.
5. Luo N., Perera C., Holton J., Ayles H., Zumla A. Spread of Neisseria meningitidis group A clone III-I meningitis epidemic into Zambia. J Infect 1998, 36:141-143.
6. Stephens D.S., Greenwood B., Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007, 369:2196-2210.
7. Molesworth A.M., Thomson M.C., Connor S.J., Cresswell M.P., Morse A.P., Shears P., et al. Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa. Trans R Soc Trop Med Hyg 2002, 96:242-249.
8. Robbins J.B., Schneerson R., Gotschlich E.C., Mohammed I., Nasidi A., Chippaux J.P., et al. Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines. Bull World Health Organ 2003, 81:745-750. [discussion 751-745].
9. Pinner R.W., Onyango F., Perkins B.A., Mirza N.B., Ngacha D.M., Reeves M., et al. Epidemic meningococcal disease in Nairobi, Kenya, 1989. The Kenya/Centers for Disease Control (CDC) Meningitis Study Group. J Infect Dis 1992, 166:359-364.
10. Daugla D., Gami J., Gamougam K., Naibei N., Mbainadji L., Narbé M., et al. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community trial. Lancet 2014, 383(9911):30.
11. Pichichero M.E. The new meningococcal conjugate vaccine. A profile of its safety, efficacy, and indications for use. Postgrad Med 2006, 119. 47-54, 64.
12. Akpede G.O. Presentation and outcome of sporadic acute bacterial meningitis in children in the African meningitis belt: recent experience from northern Nigeria highlighting emergent factors in outcome. West Afr J Med 1995, 14:217-226.
13. Armand J., Arminjon F., Mynard M.C., Lafaix C. Tetravalent meningococcal polysaccharide vaccine groups A, C, Y, W, 135, clinical and serological evaluation. J Biol Stand 1982, 10:335-339.
14. Girard M.P., Preziosi M.P., Aguado M.T., Kieny M.P. A review of vaccine research and development: meningococcal disease. Vaccine 2006, 24:4692-4700.
15. Peltola H., Makela H., Kayhty H., Jousimies H., Herva E., Hallstrom K., et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med 1977, 297:686-691.
16. Kieny M.P., LaForce F.M. The promise of conjugate vaccines for Africa. Vaccine 2007, 25(1):A108-A110.
17. Woodard J.L., Berman D.M. Prevention of meningococcal disease. Fetal Pediatr Pathol 2006, 25:311-319.
18. Safadi M.A., Barros A.P. Meningococcal conjugate vaccines: efficacy and new combinations. J Pediatr (Rio J) 2006, 82:S35-S44.
19. Jodar L., LaForce F.M., Ceccarini C., Aguado T., Granoff D.M. Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet 2003, 361:1902-1904.
20. LaForce F.M., Konde K., Viviani S., Preziosi M.P. The meningitis vaccine project. Vaccine 2007, 25(Suppl. 1):A97-A100.
21. Kim S.H., Pezzoli L., Yacouba H., Coulibaly T., Djingarey M.H., Perea W.A., et al. Whom and where are we not vaccinating? Coverage after the introduction of a new conjugate vaccine against group A meningococcus in Niger in 2010. PLoS ONE 2012, 7:e29116.
22. Ouandaogo C.R., Yameogo T.M., Diomande F.V., Sawadogo C., Ouedraogo B., Ouedraogo-Traore R., et al. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010. Vaccine 2012, 30(Suppl. 2):B46-B51.
23. Djingarey M.H., Barry R., Bonkoungou M., Tiendrebeogo S., Sebgo R., Kandolo D., et al. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine 2012, 30(2):B40-B45.
24. Immunization, Vaccines and Biologicals. Revolutionary meningitis vaccine breaks another barrier; first to gain approval to travel outside cold chain. WHO (Online) (cited 05 Dec 2013) available from www.who.int/immunization/newsroom/menafrivac_20121114/en/.
25. Trotter C.L., Andrews N.J., Kaczmarski E.B., Miller E., Ramsay M.E. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004, 364:365-367.
26. Kristiansen P.A., Diomande F., Ba A.K., Sanou I., Ouedraogo A.S., Ouedraogo R., et al. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis 2013, 56(3):354-363.
27. Sow S.O., Okoko B.J., Diallo A., Viviani S., Borrow R., Carlone G., et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011, 364:2293-2304.
28. Lennon D., Jackson C., Wong S., Horsfall M., Stewart J., Reid S., et al. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand. Clin Infect Dis 2009, 49:597-605.
29. Soriano-Gabarro M., Rosenstein N., LaForce F.M. Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project. J Health Popul Nutr 2004, 22:275-285.
30. Okoko B.J., Idoko O.T., Adegbola R.A. Prospects and challenges with introduction of a mono-valent meningococcal conjugate vaccine in Africa. Vaccine 2009, 27:2023-2029.
31. Borrow R., Goldblatt D., Andrews N., Southern J., Ashton L., Deane S., et al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. J Infect Dis 2002, 186:1353-1357.
32. Hodgson A., Forgor A.A., Chandramohan D., Reed Z., Binka F., Bevilacqua C., et al. A phase II, randomized study on an investigational DTPw-HBV/Hib-MenAC conjugate vaccine administered to infants in Northern Ghana. PLoS ONE 2008, 3:e2159.
33. Gheesling L.L., Carlone G.M., Pais L.B., Holder P.F., Maslanka S.E., Plikaytis B.D., et al. Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J Clin Microbiol 1994, 32:1475-1482.
34. Borrow R., Balmer P., Miller E. Meningococcal surrogates of protection - serum bactericidal antibody activity. Vaccine 2005, 23:2222-2227.
35. Norheim G., Aseffa A., Yassin M.A., Mengistu G., Kassu A., Fikremariam D., et al. Serum antibody responses in Ethiopian meningitis patients infected with Neisseria meningitidis serogroup A sequence type 7. Clin Vaccine Immunol 2007, 14:451-463.
36. Kayhty H., Jousimies-Somer H., Peltola H., Maketa P.H. Antibody response to capsular polysaccharides of groups A and C Neisseria meningitidis and Haemophilus influenzae type b during bacteremic disease. J Infect Dis 1981, 143:32-41.
37. Organization W.H. Requirements for meningococcal polysaccharide vaccines 1976, 594:594.
38. Siegrist C.A. Neonatal and early life vaccinology. Vaccine 2001, 19:3331-3346.
39. Holmlund E., Nohynek H., Quiambao B., Ollgren J., Kayhty H. Mother-infant vaccination with pneumococcal polysaccharide vaccine: persistence of maternal antibodies and responses of infants to vaccination. Vaccine 2011, 29:4565-4575.
40. Sangpetchsong V., Impat A., Dhiensiri K., Podhipak A. Effect of passive immunity to tetanus in DTP vaccinated infants. Southeast Asian J Trop Med Public Health 1985, 16:117-123.
41. Chandramohan D., Coleman P., Nelson C., Greenwood B. A new approach to the definition of seroconversion following vaccination in a population with high background antibody concentrations. Vaccine 2007, 25(Suppl. 1):A58-A62.
42. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 1997, 4:156-167.
43. Kshirsagar N., Mur N., Thatte U., Gogtay N., Viviani S., Preziosi M.P., et al. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine 2007, 25(1):A101-A107.
44. Robbins J.B., Myerowitz L., Whisnant J.K., Argaman M., Schneerson R., Handzel Z.T., et al. Enteric bacteria cross-reactive with Neisseria meningitidis groups A and C and Diplococcus pneumoniae types I and 3. Infect Immun 1972, 6:651-656.
45. Vann W.F., Liu T.Y., Robbins J.B. Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide. Infect Immun 1976, 13:1654-1662.
46. Guirguis N., Schneerson R., Bax A., Egan W., Robbins J.B., Shiloach J., et al. Escherichia coli K51 and K93 capsular polysaccharides are crossreactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies. J Exp Med 1985, 162:1837-1851.
47. Ali O., Aseffa A., Bedru A., Lemma T., Moti T., Workhu A., et al. Meningococcal carriage in the African meningitis belt. Trop Med Int Health 2013, 18:968-978.